Publicaciones en colaboración con investigadores/as de Tel Aviv University (26)

2024

  1. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993

  2. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831

  3. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates—2024

    Journal of Heart and Lung Transplantation, Vol. 43, Núm. 10, pp. 1529-1628.e54

  4. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 25, Núm. 4, pp. 457-468

  2. Ventricular arrhythmias in patients with hypertrophic cardiomyopathy: Prevalence, distribution, predictors, and outcome

    Heart Rhythm, Vol. 20, Núm. 10, pp. 1385-1392

2022

  1. Global multi-stakeholder endorsement of the MAFLD definition

    The Lancet Gastroenterology and Hepatology

  2. Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2301-2312

2021

  1. Cancer drug resistance induced by EMT: novel therapeutic strategies

    Archives of Toxicology, Vol. 95, Núm. 7, pp. 2279-2297

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

    European Journal of Haematology, Vol. 104, Núm. 6, pp. 594-601

  2. Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry

    Circulation: Genomic and Precision Medicine, Vol. 13, Núm. 6, pp. E003117

  3. Natural History and Risk Stratification in Andersen-Tawil Syndrome Type 1

    Journal of the American College of Cardiology, Vol. 75, Núm. 15, pp. 1772-1784

  4. Reduction in Filamin C transcript is associated with arrhythmogenic cardiomyopathy in Ashkenazi Jews

    International Journal of Cardiology, Vol. 317, pp. 133-138

2019

  1. Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients

    Journal of Cellular and Molecular Medicine, Vol. 23, Núm. 3, pp. 2125-2135

  2. The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy

    European Heart Journal, Vol. 40, Núm. 21, pp. 1671-1677

2018

  1. European expert consensus statement on therapeutic goals in Fabry disease

    Molecular Genetics and Metabolism, Vol. 124, Núm. 3, pp. 189-203

  2. Modeling peripartum cardiomyopathy with human induced pluripotent stem cells reveals distinctive abnormal function of cardiomyocytes

    Circulation

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222